PSI Webinar: HTA Submissions in the UK
Time: 10:00 - 12:00 UK time
Presenters: Jessica Purchase, Group Health Economics Manager (F. Hoffmann-La Roche Ltd, Welwyn) and Monica Daigl, HTA Statistician and Health Economist (F. Hoffmann-La Roche Ltd, Basel)
There is a simple equation for access in the UK: Access = Reimbursement + Uptake
Yet, whilst a simple and logical approach, each component is challenging to achieve.
This webinar focuses on the National Reimbursement side: the National Institute for Health and Care Excellence (NICE) - who they are, what is involved in the Health Technology Appraisal (HTA) assessment, how they make decisions.
We’ll also review where the devolved nations come in: how do the Scottish Medicines Consortium (SMC) and All Wales Medicines Strategy Group (AWMSG) differ from NICE in decision making?
Finally, through the use of a real world example, we’ll explore the key drivers and barriers experienced in decision making: specifically the challenges associated with correct comparators and predicting of long term outcomes.
This will lead to the second part of the webinar. We will focus on two advanced statistical techniques to inform health economic models: modelling of time to event endpoints such as progression free and overall survival beyond the duration of a clinical study to predict long-term outcomes; and network meta analyses to estimate the value of a drug in the absence of direct comparative evidence.
Finally, we provide our key recommendations for the future of clinical trial design, to support access for the UK market.
About the Presenters:
Jessica Purchase is a Group Health Economics Manager in the Health Economics and Strategic Pricing team in Roche UK. She joined Roche in 2016, following 5 years of Health Economics and Market Access consulting. In her role she has successfully lead on a variety of HTAs resulting in UK access in the oncology space.
Monica Daigl is a medical statistician and epidemiologist with >15 years of experience in the analysis of clinical trials and observational studies in pharma, medical device industry and academia. She joined 2014 the Global Access Center of Excellence at F. Hoffmann-La Roche as HTA Statistician and Health Economist. In her role she supports Roche affiliates with their local HTA submissions in multiple therapeutic areas.
|Non-member||£20 (plus VAT)|
Registration has now closed.